Jean-Christophe Tellier
CEO
MT
Modis Therapeutics
Modis Therapeutics develops disease-modifying therapies targeting rare genetic disorders through advanced gene editing techniques. The company aims to provide effective treatment options for patients suffering from conditions with significant unmet medical needs.
Traction 10/10Founded 2016
Oakland, United States · HQ
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$101MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many individuals suffer from rare genetic disorders with significant unmet medical needs, often lacking effective treatment options to address the underlying causes of their conditions. Traditional therapeutic approaches may only manage symptoms without targeting the genetic root of the disease.
Solution
UCB (formerly Modis Therapeutics) develops disease-modifying therapies for rare genetic disorders, employing advanced techniques to target the underlying genetic causes. The company focuses on creating impactful solutions that go beyond managing symptoms, aiming to provide patients with the ability to live their best lives. By putting patients at the heart of their research and development, UCB delivers innovative therapies designed to address significant unmet needs in severe diseases.
Target Audience
The primary beneficiaries are individuals living with rare genetic disorders and their caregivers, as well as healthcare providers specializing in the treatment of these conditions.
Features
- Utilizes advanced therapeutic techniques to target the genetic root causes of rare diseases.
- Focuses on developing disease-modifying therapies rather than just symptom management.
- Aims to provide solutions that improve the overall quality of life for patients with severe genetic disorders.